Immuron Ltd (IMRN) stock
IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.88−0.03 (-3.52%)
Close on Nov 13, 2026Market cap $7.06MP/E –Yield –
Immuron ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2026 it was -A$3.81M. The highest annual figure on record is -A$2.84M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -A$3.81M | – |
| FY2025 | Jun 30, 2025 | -A$5.29M | – |
| FY2024 | Jun 30, 2024 | -A$5.76M | – |
| FY2023 | Jun 30, 2023 | -A$3.52M | – |
| FY2022 | Jun 30, 2022 | -A$2.84M | – |
| FY2021 | Jun 30, 2021 | -A$8.34M | – |
| FY2020 | Jun 30, 2020 | -A$2.86M | – |
| FY2019 | Jun 30, 2019 | -A$4.65M | – |
| FY2018 | Jun 30, 2018 | -A$3.04M | – |
| FY2017 | Jun 30, 2017 | -A$6.72M | – |
See a number that looks wrong?